MorphoSys is focused on creating significant value for all of its stakeholders through a strategy that balances short- and long-term growth potential. By applying its proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies. The company has established successful and lasting partnerships with industry-leading companies from the pharmaceutical and biotechnology sectors. The product pipeline, one of the broadest in the antibody industry, proves the sustainable quality of MorphoSys' work. Through specific in-licensing and co-development activities, the company is adding higher value programs to the pipeline at a significant rate. Their comprehensive partnering strategy is an important feature of their business model and a vital source of MorphoSys' financial strength.
2018 was an important year for MorphoSys. The company took a large step toward their goal of becoming a fully integrated biopharmaceutical company.
Tafasitamab (MOR208) is an investigational Fc-engineered therapeutic antibody targeting CD19 that is in development for the treatment of B cell malignancies. The focus of the development program is on relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a particularly aggressive form of lymphoma, for which there are no approved treatments. Tafasitamab received breakthrough therapy designation (BTD) from the FDA in 2017 based on preliminary data from the phase 2 L-MIND study, which is evaluating the safety and efficacy of Tafasitamab in combination with lenalidomide. MorphoSys has publicly disclosed the final study data in May 2019, which will be presented at ICML and be used to support the BLA filing scheduled at the end of 2019.
To advance the development of Tafasitamab and in preparation for its planned subsequent commercialization, MorphoSys has founded MorphoSys US Inc., a wholly owned subsidiary of MorphoSys AG. An additional important step in order to increase the U.S. footprint was the successful closing of an IPO on the Nasdaq U.S. stock exchange in April 2018.